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Summary
Background Sciatica has a substantial impact on individuals and society. Stratified care has been shown to lead to better 
outcomes among patients with non-specific low back pain, but it has not been tested for sciatica. We aimed to 
investigate the clinical and cost-effectiveness of stratified care versus non-stratified usual care for patients presenting 
with sciatica in primary care.
Methods We did a two-parallel arm, pragmatic, randomised controlled trial across three centres in the UK 
(North Staffordshire, North Shropshire/Wales, and Cheshire). Eligible patients were aged 18 years or older, had a 
clinical diagnosis of sciatica, access to a mobile phone or landline number, were not pregnant, were not currently 
receiving treatment for the same problem, and had no previous spinal surgery. Patients were recruited from general 
practices and randomly assigned (1:1) by a remote web-based service to stratified care or usual care, stratified by centre 
and stratification group allocation. In the stratified care arm, a combination of prognostic and clinical criteria associated 
with referral to spinal specialist services were used to allocate patients to one of three groups for matched care 
pathways. Group 1 was offered brief advice and support in up to two physiotherapy sessions; group 2 was offered up to 
six physiotherapy sessions; and group 3 was fast-tracked to MRI and spinal specialist assessment within 4 weeks of 
randomisation. The primary outcome was self-reported time to first resolution of sciatica symptoms, defined as 
“completely recovered” or “much better” on a 6-point ordinal scale, collected via text messages or telephone calls. 
Analyses were by intention to treat. Health-care costs and cost-effectiveness were also assessed. This trial is registered 
on the ISRCTN registry, ISRCTN75449581.
Findings Between May 28, 2015, and July 18, 2017, 476 patients from 42 general practices around three UK centres were 
randomly assigned to stratified care or usual care (238 in each arm). For the primary outcome, the overall response rate 
was 89% (9467 of 10 601 text messages sent; 4688 [88%] of 5310 in the stratified care arm and 4779 [90%] of 5291 in the 
usual care arm). Median time to symptom resolution was 10 weeks (95% CI 6·4–13·6) in the stratified care arm and 
12 weeks (9·4–14·6) in the usual care arm, with the survival analysis showing no significant difference between the 
arms (hazard ratio 1·14 [95% CI 0·89–1·46]). Stratified care was not cost-effective compared to usual care.
Interpretation The stratified care model for patients with sciatica consulting in primary care was not better than usual 
care for either clinical or health economic outcomes. These results do not support a transition to this stratified care 
model for patients with sciatica.
Funding: National Institute for Health Research.
Copyright 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 
license.
Introduction
The term sciatica describes symptoms of pain radiating 
from the low back to the legs, and it can be associated with 
sensory and motor deficits.1,2 Occasionally, patients only 
have leg pain with no associated back pain. A pro lapsed 
disc causing compression of lumbar spinal nerve roots 
is the most common cause of sciatica.1,2 Sciatica has 
a substantial impact on patients and constitutes a con­
siderable health­care, social, and economic burden.3–5
As in many countries, most patients with sciatica in 
the UK are managed in primary care. For most patients, 
especially those with a short symptom duration, usual 
care comprises mostly a stepped­care approach, starting 
with conservative interventions such as advice, medica­
tions, and physiotherapy, with those patients who show no 
improvement eventually being offered imaging, specialist 
assessment, and consideration of suitability for invasive 
treatments (eg, injections or surgery).6,7 A longer symptom 
duration of sciatica is related to worse outcomes following 
both conservative and surgical treatment.8 In the absence 
of a systematic way to identify patients who might need 
more support in their care, including a referral to 
specialists for consideration of more invasive treat ments, 
there is considerable variation in practice. The current, 
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mainly stepped care, approach means that most patients 
have to show no improvement with previous interventions 
before being considered for further treat ments, resulting 
in delays in referral to spinal specialists.
A model of stratified care for patients consulting with 
non­specific low back pain, which uses a stratification tool 
to identify their risk of disability related to persistent back 
pain in order to match patients to appropriate treatments, 
has previously been shown to be both clinically and cost­
effective in the UK National Health Service (NHS).9,10 
There is insufficient evidence as to whether a similar 
approach specifically for patients presenting with sciatica 
in primary care could be beneficial.
A key challenge in the development of predictive and 
stratified care models for patients with sciatica is the 
scarce and inconsistent evidence for prognostic factors 
independently associated with outcome.11–14 To date, it has 
not been possible to predict which patients might benefit 
from surgery.15 An alternative stratification method is to 
test whether predicting and instigating early referral to 
spinal specialists improves outcomes compared to clinical 
care based on clinical judgement alone. We developed an 
adapted stratified care algorithm specifically for patients 
with sciatica presenting in primary care.16 Briefly, the 
algorithm combines information about the risk (low, 
medium, or high) of persistent disability (using the STarT 
Back tool;17 appendix p 9) with clinical criteria (current leg 
pain, pain below knee, interference with work or home 
activities, and objective sensory deficits) associated with 
referral to spinal specialist services, to allocate patients 
into one of three groups that are each matched to a care 
pathway. Patients at low risk of poor outcome, irrespective 
of clinical characteristics, are allocated to group 1 and are 
offered up to two sessions with a physiotherapist for brief 
support with self­management; patients at medium risk 
of poor outcome who have all four clinical characteristics, 
and patients at high risk of poor outcome with any three of 
the clinical characteristics, are allocated to group 3 with a 
matched care pathway of fast­track to MRI and referral to 
a spinal specialist; the remainder of patients are allocated 
to group 2 and offered up to six sessions of physiotherapy. 
The sensitivity, specificity, and positive predictive value of 
the algorithm for patient allocation to group 3 have been 
previously reported; sensitivity was 51%, specificity 73%, 
and the positive predictive value was 22% (C­statistic 0·70).16 
Details of the matched care pathways for each sciatica 
group have been previously reported in our pub lished 
protocol.18 The SCOPiC trial investigated whether this 
stratified care model led to faster resolution of sci­
atica symptoms compared with non­stratified usual care, 
and whether this approach was cost­effective. The linked 
qualitative interviews with patients and clinicians, explor­
ing their views and experi ences of the fast­track care 
pathway tested in the trial, will be reported separately.
Methods
Study design and participants
SCOPiC was a two­parallel­arm, pragmatic, randomised 
controlled trial with 1:1 allocation. An internal pilot phase 
assessed participant recruitment and follow­up rates over 
the first 8 months of recruitment, trial processes, and 
adherence to trial protocols. Progression criteria from the 
internal pilot phase to the main trial included achiev ing a 
recruitment rate of more than 70% of those eligible, and 
observing less than 25% loss to follow­up on the primary 
outcome. The internal pilot did not involve formal interim 
analysis of between­arm effects on the primary outcome 
or any other outcomes. Patients were recruited from gen­
eral practices, in areas surrounding three centres in 
the UK (North Staffordshire, North Shropshire/Wales, and 
Cheshire). Five community NHS physiotherapy services 
were involved in the trial across the three centres, and 
Research in context
Evidence before this study
We searched PubMed up to Dec 31, 2013, with the search terms 
“stratified care”, “sciatica”, and “radiculopathy”. The search was 
restricted to English language publications. We found no 
previous trials of stratified care for patients with sciatica before 
undertaking our study. Therefore, no systematic review was 
possible. The evidence considered came from previous research 
on prognostic stratified care for patients with non-specific 
lower back pain (STarT Back and IMPaCT Back studies) and a 
cohort of patients with sciatica (ATLAS study) in the primary 
care setting, from which we examined the factors predicting 
referral of patients to specialist spinal services. These previous 
studies shaped the development of the stratification algorithm 
(previously published) that was tested in this trial.
Added value of this study
Before this trial, a UK Spinal Taskforce in 2013 highlighted 
the need for better information about the clinical and 
cost-effectiveness of early referral of patients with severe 
symptoms of sciatica for consideration of secondary care 
treatments such as surgery or spinal injections. The findings of 
this trial provide the first evidence about the clinical and 
cost-effectiveness of stratified care, including a fast-track 
pathway, for patients consulting in primary care with sciatica.
Implications of all the available evidence
In a primary care setting, where most patients with sciatica are 
assessed and managed, our findings do not support a 
transition from the mainly stepped care model to this stratified 
care model. However, testing ways to deliver care 
systematically to patients with sciatica could help to reduce 
practice variation. Taking into account that the key prognostic 
factors relevant in non-specific low back pain are not 
consistent prognostic factors in sciatica, further research is 
needed to explore different stratified care models for 
this population.
See Online for appendix
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patients in the fast­track pathway were seen by NHS spinal 
specialists. Ethical approval was received from the National 
Research Ethics Service West Midlands – Solihull, UK, and 
the trial was done and analysed accord ing to the protocol.18
Potential participants were identified by electronic pop­
up computer prompts in general practice computer 
systems triggered by appropriate diagnostic or symptom 
codes,19 or by weekly reviews of practice consultation 
records. Potentially eligible participants were sent infor­
mation about the SCOPiC research clinic and the trial, 
and were invited to telephone an administrator to make 
an appointment at the SCOPiC research clinic to see a 
physio therapist. Full eligibility screening and base line 
assessments, including identification of each patient’s 
sciatica group according to the stratification algorithm, 
were done at the research clinic by study physiotherapists.
Eligible patients were aged 18 years or older, with a 
clinical diagnosis of sciatica of any severity and duration 
following clinical assessment by a physiotherapist in the 
research clinics, had access to a mobile phone or landline, 
were not receiving treatment nor had received treatment in 
the last 3 months for the same problem, were not preg­
nant, and had no previous lumbar spine surgery. Patients 
with clinical suspicion (by their general practitioner [GP] or 
the assessing physiotherapist) of serious spinal path ology 
(eg, cauda equina syndrome, fracture, spondylo arthropathy, 
malignancy, infection, or foot drop) or serious physical 
or mental co­morbidities (as judged by their GP or the 
assessing physiotherapist) were excluded. The sciatica 
case definition for this trial was based on the assessing 
physiotherapist being at least 70% confident in their clinical 
diagnosis,20,21 with at least one of the following being 
present: leg pain approximating a dermatomal distribu­
tion; leg pain worse than or as bad as back pain; leg pain 
worse with coughing, sneezing, or straining; sub jective 
sensory changes approximating a dermatomal distribu­
tion; objective neurological deficits indicative of nerve root 
compression; positive neural tension test;22,23 and (specifi­
cally for spinal claudication or spinal steno sis) leg pain 
worse with weight­bearing activities and better with sitting. 
Assessing physiotherapists recorded a specific clinical 
diagnosis of sciatica due to disc prolapse or stenosis.
Randomisation and masking
At the research clinic, eligible patients who gave written 
informed consent were randomly assigned by a computer­
generated code, to either stratified care or usual care. 
Randomisation was done with a web­based service from 
Keele Clinical Trials Unit, and was stratified by centre and 
sciatica group allocation (sciatica groups 1, 2, and 3), by 
use of random permuted blocks of varying size (2, 4, 
and 6). Patients were told that the trial was comparing 
two approaches for the treatment of sciatica, one based on 
matching patients to treatment by use of a simple tool that 
helps to decide on the treatment pathway, and one based 
on treatment needed as discussed and agreed between the 
patient and physiotherapist. Different physiotherapists 
delivered treatment to participants in each trial arm 
to avoid contamination bias; physiotherapists were not 
masked to treatment allocation. Statisticians and outcome 
assessors were masked to treatment allocation.
Procedures
In the stratified care arm, the stratification algorithm 
(figure 1) was used to allocate patients to one of three 
groups. Patients in group 1 were expected to do well and 
were therefore offered brief advice and support in up to 
two physiotherapy sessions. Group 2 was offered up to six 
physiotherapy sessions, and group 3 was fast­tracked to 
MRI and spinal specialist assessment within 4 weeks of 
randomisation.18 Physiotherapists treating patients in 
groups 1 and 2 were responsible for providing good 
clinical governance and could overrule the stratification 
algorithm recommendation for matched care pathways if 
they thought it clinically appropriate. In addition to having 
a consultation at their general practice, all participants in 
the usual care arm had a consultation with a physio­
therapist at the SCOPiC research clinic, their care was 
planned without the use of any stratification tools, and 
referrals for further physiotherapy or to other services 
were made at the discretion of the assessing physio­
therapist and in consultation with the patient.18
Outcomes
Informed by the involvement of patients before the trial, the 
primary outcome was time to first resolution of sciatica 
symptoms, defined as “completely recovered” or “much 
Figure 1: Stratification algorithm for allocating patients to sciatica groups and matched care pathways
NRS=numerical rating scale.
3 or lower
Group 1 care pathway:
brief self-management support 
(up to 2 sessions)
Group 2 care pathway: 
physiotherapy course 
(up to 6 sessions)
Group 3 care pathway:
referral to MRI and specialist 
spinal services 
All 4
3 or lower
STarT Back psychological subscale score (0–5)
2 or lower 3 or higher
Higher than 3: check if medium or high risk3 or lower: low risk 
STarT Back tool score (0–9)
Clinical characteristics score (0–4)
current leg pain (NRS >6 [0–10]), pain below knee, interference with 
work and home activities (NRS >6 [0–10]), objective sensory deficit
4 or higher
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better”, measured on a 6­point ordinal scale and collected 
via text messages (or brief telephone calls). The scale’s 
anchor was patients’ baseline symptoms when they 
attended the SCOPiC research clinic. The text message 
read: “Com pared to how you were at the SCOPiC clinic X 
weeks/months ago, how are your back and leg symptoms 
today?” Primary outcome data collection occurred weekly 
for the first 4 months for all participants, and then every 
4 weeks between 4 and 12 months’ follow­up, or until “stable 
resolution” of symptoms (defined as 2 consec utive months’ 
responses of “completely recovered” or “much better”).
Secondary clinical outcomes were collected at 4 and 
12 months by use of self­completed postal questionnaires. 
These included: global perceived change (GPC; 6­point 
ordinal scale as per primary outcome data collection), 
physical function,24 overall impact of sciatica symptoms,25 
back and leg pain intensity,26 sleep disturbance,27 fear of 
movement,28 anxiety and depression,29 risk of persistent 
back­pain related disability,17 health­related quality of life 
(EuroQoL EQ­5D­5L),30 general health,31 neuropathic pain 
symptoms,32 days lost from work and productivity loss due 
to sciatica, and satisfaction with care (appendix p 1). 
Furthermore, data were collected on health­care resource 
use and costs related to the delivery of the stratified care 
intervention and usual non­stratified care, over 12 months. 
Information was collected about serious adverse events 
and adverse events. Process outcomes included data 
on numbers of patients referred to physiotherapy and 
specialist spinal services, and were collected via patient 
question naires and hospital record reviews from participat­
ing NHS services. Where possible, we captured timing of 
referral and treatment.
We aimed to recruit 470 participants (see the statistical 
analysis plan in the appendix p 17 for further details) in 
order to detect a hazard ratio (HR) between 1·4 and 1·5 for 
time to resolution of symptoms (primary outcome) with 
80–90% power, assuming an event (resolution) rate of 
60% or greater over 12 months, 20% dropout, and intra­
class correlation for clustering by physiotherapist at the 
level of 0·01 and allowing for a coefficient of variation in 
physiotherapist cluster size of 0·65.33
Statistical analysis
All analyses were by intention to treat, and were done 
and reported following the Consolidated Standards of 
Reporting Trials guidelines.34
Figure 2: Trial profile
*More than one reason for ineligibility was possible. †Reasons (if known) for 
withdrawal as follows: not interested in further participation (n=5); seeing private 
therapist (n=2); poor health or no better (n=2); randomised in error (n=1); request 
by clinician (n=1); reason not known (n=7). One patient did not provide any data; 
nine had resolution of symptoms (five had stable symptom resolution) by the 
time of withdrawal. ‡Reasons (if known) for withdrawal as follows: not interested 
in further participation (n=4), poor health or no better (n=3), seeing private 
therapist (n=2), expected more treatment (n=2), family commitments (n=2), and 
reason not known (n=7). One patient did not provide any data; ten had resolution 
of symptoms (seven had stable symptom resolution) by the time of withdrawal. 
2719 clinic invitations sent by mail
1718 patients contacted Keele Clinical Trials 
           Unit and screened by telephone
370 not booked in clinic
   268 ineligible at telephone screening stage*
         123 no leg pain
           97 ongoing or recent physiotherapist 
                 or specialist care
           30 unable to read or speak English
           27 lumbar spine surgery
             5 pregnant
             2 aged <18 year
  97 declined telephone screening or invite to 
        clinic appointment, or both 
     5 screened by telephone but no clinic 
    appointment booked1348 booked in clinic
79 did not attend clinic appointment
717 ineligible at clinic screening*
    189 low confidence in sciatica diagnosis
    136 referred leg pain
   102 no leg symptoms
     87 ongoing or recent physiotherapy or 
           specialist care
      70 hip problem
      55 suspected serious pathology
      22 unable to read or speak English
      18 muscular problems
      14 trochanteric bursitis
        7 no access to phone
        5 meralgia parasthetica
        5 vascular claudication
        5 peripheral neuropathy
        3 suspected inflammatory arthropathy
        2 lumbar spine surgery
        1 pregnant
      18 other
76 not randomised
  53 not interested
  23 no consent given
1269 attended clinic screening
552 eligible for enrolment
476 consented and randomised
238 assigned to stratified care
53 to group 1 (centre A, n=17; centre B, n=31;  
centre C, n=5)
105 to group 2 (centre A, n=40; centre B, 
n=51; centre C, n=14)
80 to group 3 (centre A, n=40; centre B, n=31;  
centre C, n=9)
Primary outcome 4688 (88%) of 5310 patients 
followed up (via text message or phone call)
Secondary outcomes: 192 (81%) responders at 
4 months: 155 for full questionnaire responses, 
37 for minimal data collection responses; 
177 (74%) responders at 12 months: 125 for full 
questionnaire responses, 52 for minimal data 
collection responses
18 withdrawals†
238 assigned to usual care
54 to group 1 (centre A, n=16; centre B, 
n=33; centre C, n=5)
106 to group 2 (centre A, n=40; centre B, 
n=51; centre C, n=15)
78 to Group 3 (centre A, n=39; centre B, 
n=29; centre C, n=10)
Primary outcome 4779 (90%) of 5291 patients 
followed up (via text message or phone call)
Secondary outcomes: 201 (84%) responders at 
4 months: 161 for full questionnaire responses, 
40 for minimal data collection responses; 
182 (76%) responders at 12 months: 135 for full 
questionnaire responses, 47 for minimal data 
collection responses
20 withdrawals‡
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The primary, time­to­event analysis compared time 
to self­reported resolution of symptoms between the strati­
fied care and usual care arms over 12 months’ follow­up. 
The Kaplan­Meier survival analysis estimated the time 
from randomisation until reporting of first resolution of 
sciatica symptoms, and provided the relative median 
symptom resolution times of the two trial arms. Cox 
regression analysis estimated the HR for the rate of 
symptom resolution, adjusted for centre, sciatica group 
(stratifying variables), and pain duration (fixed effects), 
and accounting for clustering by physiotherapist (frailty or 
random effect). The secondary outcomes analysis (at 4 and 
12 months) used longitudinal mixed­effect regression 
models as appropriate to the outcome data being analysed, 
adjusting for the same variables as per the primary 
analysis. Time­by­intervention arm interactions and time­
by­baseline covariates were included to account for poten­
tial attrition bias. A descriptive summary of mean scores 
and frequency counts or percentages (as appropriate to the 
data) is presented for the two trial arms. For the between­
arm comparisons, mean differences (numer ical outcomes) 
and odds ratios (categorical outcomes) are presented along 
with 95% CIs and p values.
Prespecified sensitivity analyses (per protocol, based on 
alternative definitions of symptom resolution, alternative 
assumptions about missing data and interval­censoring, 
and complete case analyses—ie, those participants 
respond ing to all texts or phone calls) were done to assess 
the robustness of the primary analysis.
Stratified care 
(n=237*)
Usual care 
(n=238)
Age, years 50·7 (14·5) 53·3 (13·5)
Sex
Female 131 (55%) 130 (55%)
Male 106 (45%) 108 (45%)
Motor deficit 60 (25%) 63 (26%)
Reflex deficit 80 (34%) 79 (33%)
Sensory deficit 115 (49%) 123 (52%)
Participants with at least one 
deficit
169 (71%) 167 (70%)
Leg pain approximating 
dermatomal distribution
216 (91%) 220 (92%)
Leg pain worse than or as bad as 
back pain
173 (73%) 173 (73%)
Leg pain worse with coughing, 
sneezing, or straining
84 (35%) 75 (32%)
Pain on straight leg raise (positive 
result; stratified care; n=237, 
usual care; n=237)
199 (84%) 197 (83%)
Clinically suspected nerve root (stratified care; n=234, usual care; n=235)
L3 3 (1%) 3 (1%)
L4 13 (6%) 19 (8%)
L5 61 (26%) 74 (31%)
S1 141 (60%) 111 (47%)
More than one nerve root 5 (2%) 5 (2%)
Bilateral symptoms 5 (2%) 5 (2%)
IMD (stratified care; n=213, usual 
care; n=212)
14 228 
(7387–21 790)
15 614 
(8288–21 840)
Employed (in paid job; stratified 
care; n=236, usual care; n=236)
171 (72%) 160 (68%)
Time off work due to sciatica, in 
the last 12 months (yes), 
(stratified care; n=171, usual care; 
n=163)
84 (49%) 96 (59%)
Usual back pain intensity (NRS 
0–10; stratified care; n=237, usual 
care; n=237)
5·9 (2·7) 5·8 (2·9)
Usual leg pain intensity (NRS 
0–10; stratified care; n=237, usual 
care; n=237)
6·8 (2·2) 6·9 (2·2)
Symptom duration
<2 weeks 15 (6%) 33 (14%)
2–6 weeks 99 (42%) 98 (41%)
6–12 weeks 58 (24%) 46 (19%)
3–6 months 31 (13%) 29 (12%)
6–12 months 10 (4%) 10 (4%)
>12 months 24 (10%) 22 (9%)
Physical function (RMDQ 0–23) 11·1 (5·2) 11·3 (5·4)
SBI (0–24) 14·6 (5·0) 14·5 (5·0)
S-LANSS score (stratified care; n=218, usual care; n=227)
<12 124 (57%) 134 (59%)
≥12 94 (43%) 93 (41%)
Fear of movement (TSK 17–64) 40·4 (6·1) 40·8 (6·2)
HADS-Anxiety case
Possible 64 (27%) 51 (21%)
Probable 55 (23%) 67 (28%)
(Table 1 continues in next column)
Stratified care 
(n=237*)
Usual care 
(n=238)
(Continued from previous column)
HADS-Depression case
Possible 40 (17%) 48 (20%)
Probable 41 (17%) 39 (16%)
Sleep problem (yes) 149 (63%) 164 (69%)
General health
Excellent 11 (5%) 13 (5%)
Very good 52 (22%) 49 (21%)
Good 107 (45%) 103 (43%)
Fair 50 (21%) 60 (25%)
Poor 17 (7%) 13 (5%)
Data are n (%), mean (SD), or median (IQR). IMD=Index of Multiple Deprivation 
(1–32 844, with higher scores indicating lower levels of deprivation). 
NRS=Numerical Rating Scale (0–10, with higher scores indicating worse symptoms). 
RMDQ=Roland-Morris Disability Questionnaire (0–23, with higher scores indicating 
higher levels of disability). SBI=Sciatica Bothersomeness Index (0–24 composite 
score with higher scores indicating worse symptoms). S-LANSS=Self-report Leeds 
Assessment of Neuropathic Symptoms and Signs (possible range from 0 to 24, with 
a score of 12 or more indicating possible neuropathic pain). TSK=Tampa Scale of 
Kinesiophobia (17–64, with higher scores indicating higher fear of movement). 
HADS=Hospital Anxiety Depression Scale (0–21, with higher scores indicating higher 
levels of anxiety or depressive symptoms, with a cutoff point of ≥11 considered 
indicative of ‘probable case’ of depression or anxiety). *In the stratified care arm, 
data are presented for 237 participants and not 238, as one person was randomly 
assigned in error and did not provide any data after randomisation.
Table 1: Baseline characteristics of participants
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Prespecified subgroup analyses included sciatica group 
(1, 2, and 3) and clinical diagnosis (disc­related sciatica or 
stenosis). Median time to resolution was calculated per 
intervention arm per specified subgroup. The adjusted 
Cox proportional hazards frailty model was repeated 
including additional interaction terms for intervention 
arm by subgroups within the models.
The base­case economic analysis comprised a within­
trial cost­utility analysis, adopting an NHS perspective, 
done according to the intention­to­treat principle. Health­
care resource data were obtained from self­reported ques­
tionnaires at 4 and 12 months, and valued with unit 
costs from standard sources.35–37 Quality­adjusted life­years 
(QALYs) were calculated over a period of 12 months for 
each study participant by use of the area under the curve 
approach, controlling for imbalances in baseline utility 
scores with a multiple linear regression approach. Total 
costs and QALYs for all participants were estimated to 
calculate differences between stratified care and usual 
care. The cost per additional QALY gained was the key 
economic outcome of interest. To minimise bias, multiple 
imputation for missing costs and EQ­5D scores was done 
by the predictive mean matching method to account for 
the non­normality of the distribution of costs and EQ­5D 
values. Uncertainty around the incremental costs and 
QALYs (ie, the difference between stratified care and usual 
care) was investigated by use of the bootstrapping tech­
nique and results were presented on a cost­effectiveness 
plane. Cost­effectiveness acceptability curves were also 
used to reflect the probability of stratified care being 
cost­effective at different cost­per­QALY thresholds. The 
following sensi tivity analyses were done: a health­care 
and societal per spective; use of additional information 
including sciatica­related injections, MRIs, and spinal 
surgeries from hospital records for participating services; a 
complete­case analysis to assess the impact of missing 
costs and outcomes data; and pre­specified analyses to 
explore the cost­effectiveness of the two interventions by 
sciatica group (stratified care or usual care by sciatica 
groups 1, 2, and 3).
Full details of the statistical analyses are included in 
the statistical analysis plan (appendix p 13–28). Analyses 
were done with SPSS, version 24, and Stata, version 15. 
External trial steering and data monitoring committees 
oversaw the trial.
The trial was prospectively registered with the ISRCTN 
Registry on Nov 20, 2014 (ISRCTN75449581).
Patient and public involvement
Patient and public involvement (PPI) was supported by 
the PPI infrastructure within Keele University, Keele, UK. 
Members with experience of the condition were involved 
in the development of the full application and commented 
on the plain English summary. All members said they 
recognised the value of the trial and highlighted that 
prompt pain relief is key, given the severity of the pain, 
which informed the choice of time to symptom resolution 
Stratified 
care
Usual care Between-arm effect 
(95% CI)
p value
Physical function (RMDQ, 0–23)
4 months (stratified care; n=192, 
usual care; n=201)
6·5 (6·3) 6·2 (6·0) MD 0·43 (–0·69 to 1·54) p=0·45
12 months (stratified care; n=177, 
usual care; n=182)
5·0 (6·2) 5·5 (6·0) MD –0·53 (–1·84 to 0·78) p=0·43
Global perceived change (GPC)
4 months (stratified care; n=188, usual care; n=194)
Completely recovered 28 (15%) 26 (13%) ·· ··
Much Better 50 (27%) 59 (30%) ·· ··
Better 48 (26%) 59 (30%) OR 0·88 (0·51 to 1·53) p=0·66
No change 39 (21%) 32 (16%) ·· ··
Worse 23 (12%) 18 (9%) ·· ··
12 months (stratified care; n=174, usual care; n=176)
Completely recovered 34 (20%) 30 (17%) ·· ··
Much Better 63 (36%) 58 (33%) ·· ··
Better 34 (20%) 42 (24%) OR 1·43 (0·80 to 2·53) p=0·22
No change 30 (17%) 34 (19%) ·· ··
Worse 13 (7%) 12 (7%) ·· ··
Usual back pain (NRS 0–10)
4 months (stratified care; n=154, 
usual care; n=158)
3·8 (2·8) 3·4 (2·6) MD 0·32 (–0·30 to 0·94) p=0·31
12 months (stratified care; n=123, 
usual care; n=130)
3·2 (2·8) 2·7 (2·5) MD 0·26 (–0·48 to 1·01) p=0·49
Usual leg pain (NRS 0–10)
4 months (stratified care; n=191, 
usual care; n=197)
3·3 (2·9) 3·1 (2·8) MD 0·25 (–0·36 to 0·86) p=0·42
12 months (stratified care; n=176, 
usual care; n=178)
2·9 (2·9) 2·8 (2·8) MD 0·11 (–0·56 to 0·77) p=0·75
SBI (0–24)
4 months (stratified care; n=150, 
usual care; n=155)
7·9 (6·0) 7·5 (5·3) MD 0·26 (–1·03 to 1·55) p=0·69
12 months (stratified care; n=122, 
usual care; n=126)
6·7 (5·7) 6·5 (6·1) MD –0·42 (–1·94 to 1·11) p=0·59
S-LANSS (≥12)
4 months (stratified care; n=136, 
usual care; n=138)
35 (26%) 33 (24%) OR 1·17 (0·49 to 2·79) p=0·72
12 months (stratified care; n=98, 
usual care; n=105)
22 (22%) 22 (21%) OR 1·08 (0·39 to 2·98) p=0·88
Fear of movement (TSK, 17–64)
4 months (stratified care; n=145, 
usual care; n=154)
36·9 (8·4) 36·2 (7·4) MD 0·53 (–0·87 to 1·92) p=0·46
12 months (stratified care; n=117, 
usual care; n=122)
35·2 (8·5) 35·3 (7·8) MD –0·37 (–1·88 to 1·13) p=0·63
HADS-Anxiety case
4 months (stratified care; n=150, usual care; n=157)
Normal (0–7) 104 (69%) 103 (66%) ·· ··
Possible (8–10) 26 (17%) 37 (24%) OR 1·36 (0·59 to 3·13) p=0·48
Probable (≥11) 20 (13%) 17 (11%) ·· ··
12 months (stratified care; n=119, usual care; n=133)
Normal (0–7) 75 (63%) 97 (73%) ·· ··
Possible (8–10) 21 (18%) 16 (12%) OR 2·30 (0·94 to 5·65) p=0·070
Probable (≥11) 23 (19%) 20 (15%) ·· ··
(Table 2 continues on next page)
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as the primary outcome of the trial. PPI members 
reviewed the study documents. Two PPI members sat 
on the trial steering committee. A PPI group contributed 
to the nested qualitative interviews (reported separately) 
by advising on topic guides and contributing to the 
analysis of the qualitative data. A final PPI meeting was 
held to discuss the overall trial results and agree the key 
messages for patients and the public.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication.
Results
Between May 28, 2015, and July 18, 2017, 476 participants 
were randomly assigned from 42 general practices. 
Figure 2 shows the flow of participants through the trial. 
At the point of randomisation, in the stratified care arm, 
the algorithm for matching patients to one of the three care 
pathways was followed in all but four cases (four patients 
in group 1 had recovered by the time of their assessment 
in the SCOPiC research clinic and were not referred on 
for the two physiotherapy sessions defined in the protocol 
within the care pathway for group 1). At the point 
of randomisation, in the usual care arm, 200 patients 
were referred for further physio therapy treatment, 28 were 
deemed not to need further active treatment and were 
discharged back to their GP, and ten were referred for a 
spinal specialist consultation.
Patients in the two arms had similar key baseline 
characteristics (table 1). For the primary outcome, the 
overall response rate was 89% (9467 of 10 601 text messages 
sent; 4688 [88%] of 5310 in the stratified care arm and 
4779 [90%] of 5291 in the usual care arm). The overall 
follow­up rate of the 4 month questionnaire, including 
minimal data collection, was 83% (81% in the stratified 
care arm and 84% in the usual care arm), and that of the 
12 month questionnaire was 75% (74% in the stratified 
care arm and 76% in the usual care arm). Non­responders 
to the 4 and 12 month questionnaires were, on average, 
younger, lived in more deprived neighbourhoods (lower 
average index of multiple deprivation rank), and had 
slightly worse baseline health status than those who com­
pleted the questionnaires (appendix pp 1–2).
The internal pilot phase progression criteria were met, 
including recruitment and follow­up targets. No changes 
were made to the trial protocol.
Figure 3 summarises time to event data for the pri­
mary outcome. Median time to symptom resolution was 
10 weeks (95% CI 6·4–13·6) in the stratified care arm and 
12 weeks (9·4–14·6) in the usual care arm. This difference 
was not significant (HR 1·14; 95% CI 0·89–1·46). Details 
of the numbers of patients reporting improvements at 
each time­point are provided in the appendix (pp 2–3). The 
intra­class correlation for cluster ing by physiotherapist was 
0·026 for the cumulated occurrence, or not, of an event 
by week 48. Sensitivity analyses showed no significant 
differences between the trial arms (appendix pp 3–4). 
Prespecified subgroup analyses showed similar (non­
significant) outcomes between trial arms, except for the 
group of patients clinically diagnosed with spinal stenosis, 
for whom stratified care seemed to lead to faster symptom 
Stratified 
care
Usual care Between-arm effect 
(95% CI)
p value
(Continued from previous page)
HADS-Depression case
4 months (stratified care; n=150, usual care; n=158)
Normal (0–7) 117 (78%) 121 (77%) OR 0·99 (0·41 to 2·42) p=0·99
Possible (8–10) 18 (12%) 19 (12%) ·· ··
Probable (≥11) 15 (10%) 18 (11%) ·· ··
12 months (stratified care; n=119, usual care; n=133)
Normal (0–7) 89 (75%) 103 (77%) OR 1·24 (0·48 to 3·22) p=0·66
Possible (8–10) 18 (15%) 15 (11%) ·· ··
Probable (≥11) 12 (10%) 15 (11%) ·· ··
Sleep problem (yes)
4 months (stratified care; n=154, 
usual care; n=159)
54 (35%) 61 (38%) OR 1·59 (0·66 to 3·82) p=0·30
12 months (stratified care; n=124, 
usual care; n=132)
42 (34%) 41 (31%) OR 2·21 (0·85 to 5·72) p=0·10
General health
4 months (stratified care; n=153, usual care; n=158)
Excellent 5 (3%) 10 (6%) ·· ··
Very good 47 (31%) 35 (22%) ·· ··
Good 60 (39%) 69 (44%) OR 1·21 (0·65 to 2·24) p=0·56
Fair 32 (21%) 35 (22%) ··
Poor 9 (6%) 9 (6%) ··
12 months (stratified care; n=120, usual care; n=133)
Excellent 9 (8%) 12 (9%) ·· ··
Very good 43 (36%) 42 (32%) ·· ··
Good 39 (33%) 47 (35%) OR 1·49 (0·76 to 2·94) p=0·25
Fair 27 (23%) 24 (18%) ·· ··
Poor 2 (2%) 8 (6%) ·· ··
Time off work (yes)
4 months (stratified care; n=107, 
usual care; n=96)
45 (42%) 47 (49%) OR 1·11 (0·47 to 2·61) p=0·82
12 months (stratified care; n=75, 
usual care; n=81)
20 (27%) 15 (19%) OR 2·52 (0·85 to 7·49) p=0·095
Data are n (%) or mean (SD). MD=mean difference (stratified care minus usual care) by longitudinal linear mixed model 
adjusted for centre, group, duration of baseline symptoms (fixed effects) and clustering by physiotherapist and 
participant (random effects). OR=odds ratio (stratified care relative to usual care) by longitudinal logistic (ordinal for 
three or more categories, binary for two categories) mixed model adjusted for centre, group, duration of baseline 
symptoms (fixed effects) and clustering by physiotherapist and participant (random effects). RMDQ=Roland-Morris 
Disability Questionnaire (0–23, with higher scores indicating higher levels of disability). GPC=Global Perceived Change 
(rescaled as 1–5; 1=worse, 5=completely recovered); NRS=Numerical Rating Scale (0–10, with higher scores indicating 
worse symptoms). SBI=Sciatica Bothersomeness Index (0–24 composite score with higher scores indicating worse 
symptoms). S-LANSS=Self-report Leeds Assessment of Neuropathic Symptoms and Signs (possible range from 
0 to 24, with a score of 12 or more indicating possible neuropathic pain). TSK=Tampa Scale of Kinesiophobia 
(17–64, with higher scores indicating higher fear of movement). HADS=Hospital Anxiety Depression Scale 
(0–21, with higher scores indicating higher levels of anxiety or depressive symptoms, with a cutoff point of ≥11 
considered indicative of “probable case” of depression or anxiety).
Table 2: Secondary outcomes at 4 months and 12 months
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resolution (median 6 weeks faster resolution; HR 1·92 
[95% CI 1·01–3·65]; appendix p 11).
Table 2 summarises secondary outcomes. No signi­
ficant between­arm differences in secondary outcomes 
were observed. On average, participants in both arms 
improved over time on most outcomes. Approximately 
25% of patients did not report symptom resolution 
during follow­up (defined as “completely recovered” or 
“much better”; figure 3). Of those responding to the 
12 month questionnaire, 89 patients (43 in the stratified 
care arm and 46 in the usual care arm) reported being no 
better or being worse. The mean number of days lost 
from work due to sciatica over the 12 month follow­up 
was similar in both arms (5·48 days [SD 18·14] in the 
stratified care arm and 5·67 days [17·08] in the usual care 
arm). No related or unrelated adverse events or serious 
adverse events were reported in either trial arm. Most 
participants were satisfied with the care they received 
and the results of their care (appendix pp 4–5).
The overall median number of physiotherapy treat ­
ment sessions was similar for participants in both 
arms (2 [IQR 1–4] for the stratified care arm and 2 [0–3] for 
the usual care arm). Time to first physiotherapy appoint­
ment (for those who were referred to physiotherapy) was a 
median of 9 days (IQR 6–15) for patients in the stratified 
care arm versus 21·5 days (11–46) for those in the usual 
care arm. Treatments in the stratified care arm were 
delivered over a shorter timeframe (median 38 days 
[IQR 12·5–70] vs 66 days [29–97]) than in the usual care 
arm. Data on appoint ment numbers and timings at 
the specialist spinal clinics and treatment and referral 
decisions made are summarised in the appendix (p 5). 
Self­reported data and hospital records showed that 
22 patients in the stratified care arm and 13 in the usual 
care arm received spinal injections; patients in the 
stratified care arm received the injections more quickly 
than those in the usual care arm (60 days [IQR 41–93] vs 
161 days [113–253]), and five patients in the stratified care 
arm and eight in the usual care arm had spinal surgery, in 
similar timeframes.
Details of intervention costs, health­care resource use 
and costs, time off work, and quality of life (EQ­5D scores 
and QALY estimates) are provided in table 3 and in the 
appendix (pp 5–8) for both arms. Overall, minimal 
differences were observed in primary care, secondary care, 
and work outcomes between patients in the two trial arms, 
with the exception of slightly higher numbers of spinal 
injections in the stratified care arm versus the usual care 
arm, but fewer surgeries. As expected, stratified care was 
also associated with higher treatment costs driven by costs 
resulting from the fast­track pathway involving an MRI and 
visit to a spinal interface service. In the cost­utility analysis, 
stratified care was slightly less effective (QALYs –0·011: 
95% CI –0·035 to 0·013) and more costly (£46·21; 95% CI 
–110·60 to 187·06) than usual care, and was there­
fore dominated. The net monetary benefit was –£275 
if society’s willingness to pay for a QALY is valued 
at £20 000.
The dominance of usual care is confirmed by the low 
probability of this model of stratified care being cost­
effective at a willingness­to­pay threshold of £20 000 
(appendix p 11). Sensitivity analyses showed that stratified 
care was not a cost­effective option from a health­care 
and societal perspective when the extra information 
about spinal surgeries and injections from hospital 
records was included in the analysis (appendix p 7). The 
subgroup analyses showed considerable uncertainty 
around the main estimates of the incremental costs and 
QALYs because of the small sample size in each sciatica 
group (1, 2, and 3), but overall stratified care remained a 
non­cost­effective option in all three groups com pared 
with the usual care arm (appendix pp 8, 12).
Discussion
To our knowledge, this is the first trial to test a stratified 
care model in the primary care setting specifically for 
Figure 3: Kaplan-Meier time-to-event analysis of the primary outcome (time to first resolution of sciatica 
symptoms)
Cumulative proportion of resolved cases by week 48: 0·754 (all), 0·780 (stratified care), and 0·729 (usual care). 
HR=hazard ratio.*Estimation is limited to the largest event-free time if it is censored. 
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Adjusted HR=1·14 (95% CI 0·89–1·46)
Intervention
Stratified care
Usual care
Stratified care (censored)
Usual care (censored)
Stratified care (n=238) Usual care (n=238) Mean difference (95% CI) ICER
Mean costs, £ 663·58 (737·14) 617·37 (935·50) 46·21 (–110·60 to 187·06) Dominated
Mean QALYs 0·6599 (0·1731) 0·6713 (0·1685) –0·011* (–0·035 to 0·013) ··
Data are mean (SD), unless otherwise indicated. ICER=incremental cost-effectiveness ratio. QALY=quality-adjusted life-
year. *Adjusted for baseline utility.
Table 3: Cost-utility analysis for stratified care versus usual care
Articles
www.thelancet.com/rheumatology   Vol 2   July 2020 e409
patients with a clinical diagnosis of sciatica. We did not 
find convincing evidence that the stratified care model 
tested in this trial (combining prognostic information 
with clinical criteria) led to faster resolution of sciatica 
symptoms or benefits for other patient outcomes, com­
pared to usual care. In the stratified care arm, the median 
time to first resolution of sciatica symptoms was slightly 
shorter (by 2 weeks), but this difference was not significant. 
By 12 weeks, approximately 50% of participants in both 
arms had reported first resolution of symptoms. By the 
end of the follow­up period at 12 months, 74% of patients 
in the stratified care arm and 71% in the usual care arm 
had reported resolution of symptoms. From a health 
economics perspective, we found no evidence that the 
model of stratified care tested in this trial was a cost­
effective use of health­care resources when compared 
with usual NHS care. The usual care arm marginally 
dominated stratified care. Similar findings were observed 
in scenarios incorporating tests and treatment data from 
hospital records, and the three sciatica groups (1, 2, and 3).
Secondary outcomes analyses showed that, on average, 
participants in both trial arms reported similar, good 
improvements. Subgroup analyses were exploratory as 
the trial was not powered for these analyses, and as such 
these results should be treated with caution. The signi­
ficant result observed with stratified care for patients 
clinically diagnosed with spinal stenosis is based on a 
small number of patients and could simply be a chance 
finding. However, further investigation of this subgroup 
could be warranted.
The results of this trial, testing a sciatica­specific 
stratified care model combining prognostic factors and 
clinical indicators of referral to spinal specialists, are 
different to those showing the effectiveness of a prog­
nostic stratified care model for patients with non­specific 
low back pain.9,10 At 12 months, the percentage change in 
disability in both arms of the SCOPiC trial, 54·9% for the 
stratified care arm and 51·3% for the usual care arm 
(based on mean RMDQ values at baseline and 12 months 
of follow­up), was considerably higher than that achieved 
in the STarT Back trial of stratified care for non­specific 
low back pain9 (43·9% for the stratified care arm and 
34% for the control arm).
Potential explanations for the results of the SCOPiC 
trial include the performance of the stratification algo­
rithm in predicting referral to specialists, the natural and 
clinical course of sciatica symptoms in primary care, 
and the effectiveness of the usual care intervention. The 
algo rithm’s predictive performance in relation to refer­
ral to spinal specialists is acknowledged to be modest 
(C­statistic 0·70),16 with a sensitivity of 51%, specificity 
of 73%, and positive predictive value of 22%, and a 
number of patients fast­tracked to MRI and specialist 
assessment might not have needed this care pathway. 
Additionally, our qualita tive interview data, which will be 
published elsewhere, high lighted that for patients with a 
short dura tion of symptoms, clinicians were reluctant to 
consider invasive treatments such as injections and 
surgery before con servative treat ment options were tried 
first, and before sufficient time for natural improvement 
had passed. As mentioned previously, no factors have 
been consistently shown to be associated with outcome in 
sciatica,11–14 and thus would be useful to guide clinical 
decision making about early referral to spinal specialists. 
The stratified care model tested in this trial was designed 
to help with identification of patients who were likely to 
be referred to specialists at some point and instigating 
this referral early in the patient’s presentation, in addition 
to matching the remainder of patients to conservative 
packages of care early on. However, the good improvement 
achieved by most patients in both arms, including those in 
sciatica group 3 who had the highest baseline levels of 
pain and disability (with approximately a fifth in both 
arms reporting recovery within 4 weeks from randomisa­
tion), is indicative of an overall favourable natural and 
clinical course despite the initial high pain and incapacity 
levels, and points to the fact that the current prognostic 
factors associated with outcome or with early referral to 
specialists are not adequately cap turing the population 
most likely to benefit from such a treatment pathway.
In the usual care arm, all participants were seen by a 
physiotherapist (at the point of randomisation), and the 
majority were referred for physiotherapy treatment. We 
chose this model for recruiting patients into the trial, as 
other trials aiming to recruit patients with sciatica in 
general practices alone were not successful and were 
discontinued.38 The consequence of this recruitment 
model was that a larger proportion of participants received 
more care than they would have if the care been solely 
directed by their GP. It is possible that the usual care 
intervention in this trial might have been more effective 
than the care usually received in the general practice 
setting in the UK.
Strengths of the trial include the target sample size 
being reached, the high follow­up rate for the primary 
outcome and overall good adherence to matched care 
pathways in the stratified care arm, and the face validity of 
the stratified care model tested, which was developed and 
agreed by all stakeholders involved in the management of 
patients with sciatica, and was developed with previous 
data from a similar primary care population.16
Limitations of our trial include the lack of external 
validation of the stratification algorithm before using it 
in this trial, and the fact that the trial design we used 
does not allow differentiation between the effect of the 
stratification algorithm (the subgrouping) from that of 
the matched care pathways. Additionally, the trial was not 
powered to detect differences at the level of each of the 
three sciatica groups, and therefore the conclusions 
apply to the overall stratified care approach for patients 
with sciatica consulting in primary care.
In conclusion, the results of this trial do not support a 
transition to this model of stratified care for patients 
presenting with sciatica in primary care. Future research 
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needs to identify consistent factors that predict outcome 
or treatment response in patients with sciatica, to inform 
new models of stratified care for patients with sciatica. 
Until such a time that prognostic models offer a clear 
advantage to clinical decision making in this population, 
testing ways to systematically deliver care for patients with 
sciatica could help to reduce unhelpful practice variation.
Contributors
KK, ML, and NEF had full access to the data and take responsibility for 
data integrity and accuracy of data analysis. NEF, KK, KMD, DAvdW, 
JCH, MA, CDM, and EMH conceived the trial. NEF, KK, ML, KMD, 
DAvdW, MA, JCH, SJ, CDM, and EMH obtained funding. NEF was the 
chief investigator. All authors participated in the design and conduct of 
the trial. KK produced the first draft of the manuscript. ML, RO, JK, and 
SJ led the statistical analysis with input from KK and NEF. MR and 
GH led the administrative, technical, and material support. All authors 
contributed to the drafting and approval of the final manuscript.
Declaration of interests
KK reports grants from the National Institute for Health Research and 
the Higher Education Funding Council for England. ML, KMD, MA, 
CDM, EMH, DAvdW, and NEF report grants from the National Institute 
of Health Research (NIHR). JCH reports grants from the NIHR, 
honoraria from lectures relating to the STarT Back trial findings. 
SJ reports grants from the NIHR, personal fees from independent 
advisor work at Pfizer chronic advisory board meeting (November, 2018) 
outside the submitted work. All other authors declare no competing 
interests.
Data sharing
Metadata, including the study protocol, statistical analysis plan, data 
dictionaries, and key study documents (patient information leaflet, blank 
or coded case report forms, and consent form), will be deposited on a 
publicly accessible repository. De­identified individual participant data 
that underlie the results from this trial will be securely stored on servers 
approved by a government­backed cyber security scheme and made 
available to bona­fide researchers upon reasonable request via our 
controlled access procedures. Unless there are exceptional 
circumstances, data will be available upon publication of main trial 
findings and with no end date. Data requests and enquiries should be 
directed to primarycare.datasharing@keele.ac.uk. We encourage 
collaboration with those who collected the data, to recognise and credit 
their contributions. The data generated from this trial will remain the 
responsibility of the sponsor. Release of data will be subject to a data use 
agreement between the sponsor and the third party requesting the data. 
De­identified individual patient data will be encrypted upon transfer.
Acknowledgments
This study was funded by the National Institute for Health Research 
(NIHR) Health Technology Assessment Programme (NIHR HTA project 
number 12/201/09). The views and opinions expressed therein are those 
of the authors and do not necessarily reflect those of the HTA 
programme, NIHR, NHS, or the Department of Health and Social Care. 
NEF was supported through an NIHR Research Professorship 
(NIHR­RP­011–015), KK was supported through a HEFCE Senior Clinical 
Lecturer award. EMH and NEF are NIHR Senior Investigators. 
CMD was funded by an NIHR Research Professorship in General Practice 
(NIHR­RP­2014–04–026), the NIHR School for Primary Care Research 
and NIHR Collaborations for Leadership in Applied Health Research and 
Care West Midlands. We thank all the participants and general practices 
that participated in the SCOPiC trial, the Midlands Partnership NHS 
Foundation Trust, the Robert Jones and Agnes Hunt Orthopaedic 
Hospital NHS Foundation Trust, and Shropcom and the Mid­Cheshire 
NHS Foundation Trust for hosting the trial, all the NHS managers who 
facilitated the conduct of the trial, all the physiotherapists (community 
physiotherapy and interface settings) that participated in the recruitment 
and treatment of patients in the trial, the NIHR West Midlands Clinical 
Research Network, the Clinical Research Network Physiotherapy research 
facilitators (Lucy Huckfield, Yvonne Rimmer, and Katrina Humphries), 
members of the PPIE group from Keele for their contribution, and Keele 
Clinical Trials Unit (CTU). The trial team thanks and acknowledges the 
members of our Trial Steering Committee (Suzanne McDonough (chair), 
Phil Hannaford, Jeremy Fairbank, Catrin Tudur­Smith, Stephen Tatton, 
and Robert Taylor) and the Data Monitoring Committee (Ricky Mullis 
(chair), Nicola Walsh, Karla Hemming, and Terence O’Neill) for their 
valuable advice and support during the trial.
References
1 Koes B, van Tulder M, Peul W. Diagnosis and treatment of sciatica. 
BMJ 2007; 334: 1313–17.
2 Valat J, Genevay S, Marty M, Rozenberg S, Koes B. Sciatica. 
Best Pract Res Clin Rheumatol 2010; 24: 241–52.
3 van Tulder MW, Koes BW, Bouter LM. A cost­of­illness study of 
back pain in the Netherlands. Pain 1995; 62: 233–40.
4 Konstantinou K, Hider SL, Jordan J, Lewis M, Dunn KM, Hay E. 
The impact of low back­related leg pain on outcomes as compared 
with low back pain alone: a systematic review of the literature. 
Clin J Pain 2013; 29: 644–54.
5 Hider SL, Whitehurst DGT, Thomas E, Foster NE. Pain location 
matters: the impact of leg pain on healthcare use, work disability 
and quality of life in patients with low back pain. Eur Spine J 2014; 
24: 444–51.
6 NICE. Low back pain and sciatica in over 16s: assessment and 
management. NICE guideline NG59. Nov 30, 2016. https://www.
nice.org.uk/guidance/ng59 (accessed May 1, 2020). 
7 NHS England. National low back and radicular pain pathway 2017. 
Including Implementation of NICE guidance NG59. June 30, 2017. 
https://www.boa.ac.uk/uploads/assets/e26cc007­74c3­4b22­
94e408dd54ac79da/spinal%20pathfinder.pdf (accessed May 1, 2020).
8 Rihn JA, Hilibrand AS, Radcliff K, et al. Duration of symptoms 
resulting from lumbar disc herniation: Effect on treatment 
outcomes. J Bone Joint Surg Am 2011; 93: 1906–14
9 Hill J, Whitehurst D, Lewis M, et al. Comparison of stratified 
primary care management for low back pain with current best 
practice (STarT Back): a randomised controlled trial. Lancet 2011; 
378: 1560–71.
10 Foster N, Mullis R, Hill J, et al. Effect of stratified care for low back 
pain in family practice (IMPaCT Back): a prospective population­
based sequential comparison. Ann Fam Med 2014; 12: 102–11.
11 Peul W, Brand R, Thomeer R, Koes B. Improving prediction of 
‘inevitable’ surgery during non­surgical treatment of sciatica. Pain 
2008; 138: 571–76.
12 Ashworth J, Konstantinou K, Dunn K. Prognostic factors in 
non­surgically treated sciatica: a systematic review. 
BMC Musculoskelet Disord 2011; 12: 208.
13 Verwoed A, Luijsterburg P, Lin C, Jacobs W, Koes B, Verhagen A. 
Systematic review of prognostic factors predicting outcome in 
non­surgically treated patients with sciatica. Eur J Pain 2013; 
17: 1126–37.
14 Konstantinou K, Dunn K, Ogollah R, et al. Prognosis of sciatica and 
back­related leg pain in primary care: the ATLAS cohort. Spine 2018; 
18: 1030–40.
15 Arts M, Peul W. Timing and minimal access surgery for sciatica: 
a summary of two randomised trials. Acta Neurochir (Wien) 2011; 
153: 967–74.
16 Konstantinou K, Dunn KM, van der Windt D, et al. Subgrouping 
patients with sciatica in primary care for matched care pathways: 
development of a subgrouping algorithm. 
BMC Musculoskeletal Disord 2019; 20: 313.
17 Hill J, Dunn K, Lewis M, et al. A primary care back pain screening 
tool: identifying patient subgroups for initial treatment. 
Arthritis Rheumatol Arthritis Care Res 2008; 59: 632.
18 Foster N, Konstantinou K, Lewis M, et al. The clinical and 
cost­effectiveness of stratified care for patients with sciatica: 
the SCOPiC randomised controlled trial protocol. 
BMC Musculoskelet Disord 2017; 18: 172.
19 Hassey A, Gerrett D, Wilson A. A survey of validity and utility of 
electronic patient records in general practice. BMJ 2001; 322: 1401–05.
20 Genevay S, Courvoisier DS, Konstantinou K, et al. Clinical 
classification criteria for neurogenic claudication caused by lumbar 
spinal stenosis. The N­CLASS criteria. Spine J 2018; 18: 941–47.
21 Genevay S, Courvoisier DS, Konstantinou K, et al. Clinical 
classification criteria for radicular pain caused by lumbar disc 
herniation: the RAPIDH criteria (RAdicular PaIn caused by Disc 
Herniation). Spine J 2017; 17: 1464–71.
Articles
www.thelancet.com/rheumatology   Vol 2   July 2020 e411
22 Lin C, Verwoerd A, Maher C, et al. How is radiating leg pain 
defined in randomized controlled trials of conservative treatments 
in primary care? A systematic review. Eur J Pain 2014; 18: 455–64.
23 Verwoerd A, Mens J, El Barzouhi A, Peul W, Koes B, Verhagen A. 
A diagnostic study in patients with sciatica establishing the 
importance of localization of worsening of pain during coughing, 
sneezing and straining to assess nerve root compression on MRI. 
Eur Spine J 2016; 25: 1389–92.
24 Roland M, Morris R. A study of the natural history of back pain. 
Part 1: development of a reliable and sensitive measure of disability 
in back pain. Spine 1983; 8: 141–44.
25 Patrick DL, Deyo RA, Atlas SJ, Singer DE, Chapin A, Keller RB. 
Assessing health­related quality of life in patients with sciatica. 
Spine 1995; 20: 1899–908.
26 Dunn KM, Jordan KP, Croft PR. Recall of medication use, self­care 
activities and pain intensity: a comparison of daily diaries and 
self­report questionnaires among low back pain patients. 
Prim Health Care Res Dev 2010; 11: 93–102.
27 Jenkins DC, Stanton B, Niemcryk SJ, Rose RM. A scale for the 
estimation of sleep problems in clinical research. J Clin Epidemiol 
1988; 41: 313–21.
28 Kori SH, Miller RP, Todd DD. Kinesphobia: a new view of chronic 
pain behaviour. Pain Manag 1990; 3: 35–43.
29 Zigmond AS, Snaith RP. The hospital anxiety and depression scale. 
Acta Psychiatr Scand 1983; 67: 361–370.
30 Herdman M, Gudex C, Lloyd A, et al. Development and preliminary 
testing of the new five­level version of EQ­5D (EQ­5D­5L). 
Qual Life Res 2011; 20: 1727–36.
31 Ware JNJ. SF­36 Health survey update. Spine 2000; 25: 3130–39.
32 Bennett MI, Smith BH, Torrance N, Potter J. The S­LANSS score 
for identifying pain of predominantly neuropathic origin: validation 
for use in clinical and postal research. J Pain 2005; 6: 149.
33 Elridge SM, Ashby D, Kerry S. Sample size for cluster randomized 
trials: effect of coefficient of variation of cluster size and analysis 
methods. Int J Epidemiol 2006; 35: 1292–300.
34 Moher D, Hopewell S, Schulz K, Montori V, Gøtzsche P, 
Devereaux P. CONSORT: CONSORT 2010 explanation and 
elaboration: updated guidelines for reporting parallel group 
randomised trials. Int J Surg 2012; 10: 28–55.
35 Department of Health. National schedule of reference costs: 
2016–2017. London: Department of Health, 2018. 
https://improvement.nhs.uk/resources/reference­costs/ 
(accessed May 1, 2020).
36 Curtis L, Burns A. Unit costs of health and social care, Personal 
Social Service Research Unit, University of Kent, Canterbury. 
Dec 13, 2018. https://kar.kent.ac.uk/70995/ (accessed May 1, 2020). 
37 Joint Formulary Committee. BNF—British National Formulary 
(online). London: BMJ Group and Pharmaceutical Press. 
https://bnf.nice.org.uk/ (accessed May 27, 2020).
38 van der Gaag WH, van den Berg R, Koes BW. Discontinuation of a 
randomised controlled trial in general practice due to unsuccessful 
patient recruitment. BJGP Open 2017; 1: bjgpopen17X101085.
